Cytosorbents FY2024 EPS Forecast Reduced by HC Wainwright

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Cytosorbents in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings per share of ($0.30) for the year, down from their prior forecast of ($0.29). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.89 million during the quarter, compared to the consensus estimate of $9.73 million. During the same period in the prior year, the firm earned ($0.14) earnings per share.

Several other analysts have also recently issued reports on the company. StockNews.com began coverage on Cytosorbents in a research note on Sunday. They set a “hold” rating on the stock. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Trading Down 4.5 %

NASDAQ:CTSO opened at $0.93 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97. Cytosorbents has a one year low of $0.70 and a one year high of $2.15. The business’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $1.01. The stock has a market cap of $50.63 million, a price-to-earnings ratio of -2.57 and a beta of 0.56.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently bought and sold shares of the stock. CM Management LLC grew its holdings in Cytosorbents by 98.8% during the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after acquiring an additional 410,000 shares during the period. Avenir Corp increased its position in shares of Cytosorbents by 4.0% in the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after acquiring an additional 121,294 shares in the last quarter. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. Finally, Atomi Financial Group Inc. purchased a new position in Cytosorbents during the 3rd quarter valued at about $51,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.